echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The results of the national talks are released. The full analysis of key products involves Hengrui, Rongchang, and Geli Pharmaceuticals, etc.

    The results of the national talks are released. The full analysis of key products involves Hengrui, Rongchang, and Geli Pharmaceuticals, etc.

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    1.
    The results of medical insurance negotiations are released, and 
    67 new items are added for negotiation

    1.
    The results of medical insurance negotiations are released, and 
    67 new items are added for negotiation

    On December 3, the National Medical Insurance Administration held a press conference to announce the results of the 2021 National Medical Insurance Drug List adjustment.
    A total of 74 drugs were added to the list and 11 drugs were transferred out of the list.
    Among them, a total of 67 exclusive varieties were added to the negotiation.
    a

    .
    Unlike the 2020 National Medical Insurance Drug List which will be implemented on March 1, 2021, the 2021 National Medical Insurance Drug List will be implemented on January 1, 2022

    .

    From the perspective of the rate of decrease, the average price reduction of 67 drugs entered through negotiations this time was 61.
    7%, the price reduction of oncology drugs reached 64.
    88%, and the highest price reduction reached 93.
    97%

    .

    As an important catalyst for increasing the volume of drugs, medical insurance negotiations are an important link between the research and development and commercialization of innovative drugs
    .
    Although the cost of including medical insurance is a substantial profit, in the volume-price game, drugs can often enjoy the dividends of drugs entering the hospital and the increase in demand for new patients, and ultimately bring incremental contributions to varieties through volume-for-price

    .
    Therefore, it is worth paying attention to the 67 exclusive varieties transferred in the negotiation

    .

    2.
    Analysis of newly added key products in medical insurance negotiations in 2021

    2.
    Analysis of newly added key products in medical insurance negotiations in 2021

    The newly-added products in this national medical insurance negotiation mainly involve 18 A-share and Hong Kong-share pharmaceutical and biological companies.
    Among them, Hengrui Pharmaceuticals has a total of four innovative drugs newly included in the 2021 medical insurance catalog, leading in number, namely remazolam tosylate for injection.
    , Fluzoparil Capsules, Hetropopaethanolamine Tablets, and Azilsartan Tablets; Two new drugs are included in the 2021 medical insurance list by Golly Pharmaceuticals and Rongchang Biologics, namely danorevir sodium tablets and ravi hydrochloride Davir tablets, vedicitumumab for injection, and taltacept for injection

    .

    Chart: The number of newly-added products of the national medical insurance negotiation enterprises

    1.
    Hengrui Medicine

    For Hengrui Medicine, a total of four products have been successfully included in the medical insurance catalog
    .
    In general, after remazolam tosylate is included in the medical insurance, it is expected to stand out with a wider indications layout and quickly expand the market.
    However, Renfu’s remazolam besylate is also fast and new indications.
    On the way; fluzoparib, pamipacli, niraparib, and olaparib are standing on the stage of medical insurance and competing on the same stage; hytrobopar ethanolamine is the only category approved for SAA in China Medicine

    .

    Remazolam tosylate is a short-acting GABAa receptor agonist with fast onset and rapid failure.
    It has almost no inhibition on the respiratory system and cardiovascular system.
    At the same time, it is metabolized by tissue esterases and the metabolites are inactive

    .
    Compared with remazolam, remazolam tosylate is a salt-modified compound of remazolam, with higher stability and faster onset

    .
    At present, remazolam tosylate has been approved for routine gastroscopy sedation, colonoscopy diagnosis and treatment sedation, and induction and maintenance of general anesthesia, which are similar to Renfu Pharmaceutical's remazolam besylate for injection.
    Than, the indications are more extensive

    .

    Fluzoparib capsules are small molecule PARP inhibitors, which can inhibit the DNA repair process in BRCA1/2 dysfunctional cells, induce cell cycle arrest, and then inhibit tumor cell proliferation
    .
    In December 2020, NMPA approved the marketing application of fluzoparib for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer patients with germline BRCA mutation (gBRCAm) who have undergone second-line and above chemotherapy Treatment

    .

    Hetropopaethanolamine is an orally absorbed small molecule non-peptide thrombopoietin receptor (TPOR) agonist, which activates TPOR-dependent STAT and TPOR by selectively binding to the transmembrane region of the thrombopoietin receptor The MAPK signal transduction pathway stimulates the proliferation and differentiation of megakaryocytes to produce platelets to increase platelets
    .
    Hetropopaethanolamine tablets were approved for marketing in June 2021.
    They are used for chronic primary immune thrombocytopenia that has not responded well to treatments such as glucocorticoids and immunoglobulins that have an increased risk of bleeding due to thrombocytopenia and clinical conditions.
    Adult patients with severe aplastic anemia (ITP), as well as adults with severe aplastic anemia (SAA) who do not respond well to immunosuppressive therapy

    .

    Azilsartan is an angiotensin II receptor antagonist (ARB) class of antihypertensive drugs.
    Azilsartan binds to angiotensin II type 1 receptor (AT1) to antagonize angiotensin II, thereby Inhibit vasoconstriction and reduce the tension of peripheral blood vessels, showing a hypotensive effect

    .
    Hengrui's Azilsartan tablets will be listed in June 2021, which is the first domestic imitation approved for listing

    .

    2.
    Rongchang Biological

    Rongchang Biotech can be regarded as the big winner of this medical insurance negotiation.
    Both of the company's products have been successfully included in medical insurance, and the volume of innovative drugs can be expected

    .
    For Tatacept, the inclusion of medical insurance is expected to narrow the price difference with belimumab and enhance the market competitiveness of the product; for vedicitumumab, as the first ADC product to be included in medical insurance, the negotiation result is expected to become a domestic product.
    A benchmark for ADC drug pricing in the future

    .

    Vedicitumumab for injection is an antibody-conjugated drug (ADC), approved for marketing in June 2021, for HER2 overexpression locally advanced or metastatic gastric cancer that has received at least two systemic chemotherapy
    .
    The drug structure of vedicitumumab for injection includes three parts: (1) anti-human epidermal growth factor receptor 2 extracellular domain (HER2 ECD) antibody; (2) linker (MC-Val-Cit-PAB, Linker) ; (3) Cytotoxic monomethyl auristatin E (MMAE)

    .
    As the first HER2 ADC drug approved for advanced gastric cancer indications, the inclusion of vedicitumumab in medical insurance is of great significance and is expected to become a benchmark for the future pricing of domestic ADC drugs

    .

    Tacitazep for injection is a TACI-Fc fusion protein drug that prevents B lymphocyte stimulating factor (BLyS) and proliferation inducing ligand (APRIL) from binding to BAFF-R, BCMA and TACI receptors expressed on the surface of B cells , Inhibit BLyS and APRIL signal transduction, and inhibit the development and survival of mature B cells and plasma cells
    .
    In March 2021, Taltazep was approved for marketing, and its indication is systemic lupus erythematosus

    .
    After being included in medical insurance, the price difference between tytacept and belimumab is expected to be greatly reduced, providing patients with lupus erythematosus with better medication options

    .

    3.
    Kerry Pharmaceuticals

    Following the failure of medical insurance in 2019 and 2020, Danoprevir sodium tablets of Kerry Pharmaceuticals were finally included in medical insurance.
    Although the medical insurance was late, it was not absent after all

    .
    Regarding the inclusion of the two types of medical insurance, the company is full of confidence in the future development.
    On December 3, it repurchased 689,000 shares on the Hong Kong Stock Exchange, and the company's stock price rose 11% intraday

    .

    Danorevir sodium tablets are already an old friend of hepatitis C patients.
    Danorevir sodium tablets were launched in 2018.
    It is the first domestically-developed DAA class 1 new drug, breaking Gilead, AbbVie, Bristol-Myers Squibb and other U.
    S.
    pharmaceutical companies to C Monopoly of the hepatitis treatment drug market

    .
    Lavidavir hydrochloride tablets is an NS5A inhibitor, launched in July 2020.
    The indications are danoprevir sodium tablets and ribavirin fortified with ritonavir for the treatment of newly diagnosed gene 1b Non-cirrhotic adult patients with chronic hepatitis C virus infection

    .

    4.
    Brief analysis of other key varieties

    Iris-Vometinib mesylate is the third-generation EGFR-TKI, which was approved for marketing in March 2021, officially opening a fair competition with osimertinib and ametinib
    .

    Haisco—Cyclopofol is a GABAA receptor agonist and an anesthetic sedative.
    Compared with propofol, cyclopofol has a stronger affinity for GABAA receptors, and its therapeutic index is approximately 2.
    4 times that of propofol.
    It is included in medical insurance It has a positive effect on entering the hospital and increasing the volume of products

    .

    Betta Pharmaceuticals-Ensatinib is an ALK inhibitor, used for the treatment of ALK-positive non-small cell lung cancer.
    With Ensatinib included in the medical insurance, Betta Pharmaceuticals finally got rid of icotinib.
    "The problem of walking, in addition, relying on the mature sales team built by Icotinib, the expected volume of Ensatinib is high

    .

    Nuocheng Jianhua——Obutinib is a BTK inhibitor used for the treatment of mantle cell lymphoma and other treatments.
    Considering that both Zebutinib and Ibrutinib have been included in the medical insurance, abrutinib is included in the medical insurance this time It is very important for the product volume

    .
    At the same time, as Nuocheng Jianhua's first commercialized drug, the commercialization success of Obutinib has a demonstrative effect

    .

    Hisun Pharmaceuticals-Haibo Mebu is the first oral intestinal cholesterol absorption inhibitor in China and the second in the world
    .
    It
    provides a new medication choice for patients who cannot tolerate high-dose statins .
    Medical insurance is expected to give the drug the wings to take off, but the high dependence on the sales of statin drugs may still be the bottleneck of the increase in the volume of ezetimibe and hypermebe

    .

    3.
    Summary

    3.
    Summary

    Although the results of this year's medical insurance negotiations have been announced, the prices of most drugs have not been announced
    .
    Taking into account that the new version of the medical insurance catalog will be implemented on January 1, 2022, the extent of drug price reductions can be further seen through the flow of drugs at that time

    .
    Regarding medical insurance negotiations, it cannot be simply interpreted as a favorable policy of "quantity for price".
    After some drugs are included in medical insurance, although sales have increased rapidly, due to the sharp decline in prices, sales eventually declined instead of increasing

    .
    In addition, due to the inclusion of competing products in medical insurance, fierce competition may weaken the advantages of medical insurance

    .
    In the final analysis, the core of medical insurance lies in the trade-off relationship between volume and price, which deserves special attention

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.